Your browser doesn't support javascript.
loading
Cystic fibrosis survival outcomes following second lung transplant: The north American experience.
Alshehri, Moayad; Ramos, Kathleen J; Sykes, Jenna; Ma, Xiayi; Stanojevic, Sanja; Quon, Bradley S; Marshall, Bruce C; Cromwell, Elizabeth; Ostrenga, Joshua S; Faro, Albert; Elbert, Alexander; Todd, Jonathan; Chaparro, Cecilia; Goss, Christopher H; Stephenson, Anne L.
Afiliação
  • Alshehri M; Department of Respirology, St. Michael's Hospital, Toronto, Ontario, Canada.
  • Ramos KJ; Unit of Pulmonology, Internal Medicine Department, King Saud University, Riyadh, Saudi Arabia.
  • Sykes J; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington Medical Center, Seattle, Washington, USA.
  • Ma X; Department of Respirology, St. Michael's Hospital, Toronto, Ontario, Canada.
  • Stanojevic S; Department of Respirology, St. Michael's Hospital, Toronto, Ontario, Canada.
  • Quon BS; Department of Community Health and Epidemiology, Dalhousie University, Halifax, Nova Scotia, Canada.
  • Marshall BC; Centre for Heart Lung Innovation, Department of Medicine, University of British Columbia, Vancouver, British Columbia, Canada.
  • Cromwell E; Cystic Fibrosis Foundation, Bethesda, Maryland, USA.
  • Ostrenga JS; Cystic Fibrosis Foundation, Bethesda, Maryland, USA.
  • Faro A; Cystic Fibrosis Foundation, Bethesda, Maryland, USA.
  • Elbert A; Cystic Fibrosis Foundation, Bethesda, Maryland, USA.
  • Todd J; Cystic Fibrosis Foundation, Bethesda, Maryland, USA.
  • Chaparro C; Cystic Fibrosis Foundation, Bethesda, Maryland, USA.
  • Goss CH; Toronto Lung Transplant Program, University Health Network, Toronto, Canada.
  • Stephenson AL; Division of Pulmonary, Critical Care and Sleep Medicine, Department of Medicine, University of Washington Medical Center, Seattle, Washington, USA.
Clin Transplant ; 37(11): e15097, 2023 11.
Article em En | MEDLINE | ID: mdl-37563332
INTRODUCTION: Re-transplant is an option for those who develop end-stage lung disease due to rejection; however, little data exist following re-transplantation in cystic fibrosis (CF). METHODS: Data from the Canadian CF Registry and US CF Foundation Patient Registry supplemented with data from United Network for Organ Sharing were used. Individuals who underwent a 2nd lung transplant between 2005 and 2019 were included. The Kaplan-Meier method was used to estimate the probability of survival post-second transplant at 1, 3, and 5-years. RESULTS: Of those people who were waitlisted for a second transplant (N = 818), a total of 254 (31%) died waiting, 395 (48%) were transplanted and 169 (21%) people were alive on the waitlist. Median survival time after 2nd lung transplant was 3.3 years (95% CI: 2.8-4.1). The 1-, 3- and 5-year survival rates were 77.4% (95% CI: 73.1-82%), 52% (95% CI: 46.7-58%) and 39.4% (95% CI: 34.1-45.6%). CONCLUSIONS: Survival following second lung transplant in CF patients is lower than estimates following the first transplant. Over half of subjects who are potentially eligible for a second transplant die without receiving a second organ. This warrants further investigation.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Pulmão / Fibrose Cística Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Clin Transplant Assunto da revista: TRANSPLANTE Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Transplante de Pulmão / Fibrose Cística Limite: Humans País/Região como assunto: America do norte Idioma: En Revista: Clin Transplant Assunto da revista: TRANSPLANTE Ano de publicação: 2023 Tipo de documento: Article País de afiliação: Canadá